NYSEAMERICAN:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis $2.95 -0.03 (-1.01%) Closing price 04:10 PM EasternExtended Trading$2.97 +0.02 (+0.68%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Perspective Therapeutics Stock (NYSEAMERICAN:CATX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CATX alerts:Sign Up Key Stats Today's Range$2.93▼$3.1350-Day Range$2.93▼$4.7152-Week Range$1.96▼$6.16Volume7.66 million shsAverage Volume1.34 million shsMarket Capitalization$336.45 millionP/E RatioN/ADividend YieldN/APrice Target$12.63Consensus RatingBuy Company Overview Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington. Read More Perspective Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreCATX MarketRank™: Perspective Therapeutics scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingBuy Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 1 strong buy rating, 8 buy ratings, no hold ratings, and no sell ratings.Upside PotentialPerspective Therapeutics has a consensus price target of $12.63, representing about 328.0% upside from its current price of $2.95.Amount of Analyst CoveragePerspective Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Perspective Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($1.11) to ($1.15) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Perspective Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.54% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 11.31, which indicates bearish sentiment.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 1.17%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 6 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows6 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.99% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CATX Stock News HeadlinesH.C. Wainwright Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)June 5, 2026 | theglobeandmail.comPiper Sandler Sticks to Its Buy Rating for Perspective Therapeutics (CATX)June 5, 2026 | theglobeandmail.comDo NOT buy or sell SPCX before reading thisSpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much as 7,100% - buying SPCX stock isn't the best way to profit. A hidden SpaceX division, already live across the American South and unrelated to its launch business, could be worth 100 times more than SpaceX's core operations. Rob Spivey, Director of Research at Altimetry, breaks down exactly what it is and how to position for it.June 18 at 1:00 AM | Altimetry (Ad)Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trialJune 3, 2026 | proactiveinvestors.comPerspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a StudyJune 3, 2026 | globenewswire.comPerspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical PipelineJune 1, 2026 | tipranks.comPerspective Therapeutics shareholders approve directors and governance itemsMay 27, 2026 | tipranks.comPerspective Therapeutics, Inc. Reports Positive Updates on Clinical Programs at ASCO 2026, Highlighting Efficacy and Safety of [212Pb]VMT-α-NET, [212Pb]VMT01, and [212Pb]PSV359May 21, 2026 | quiverquant.comQSee More Headlines CATX Stock Analysis - Frequently Asked Questions How have CATX shares performed this year? Perspective Therapeutics' stock was trading at $2.75 at the start of the year. Since then, CATX stock has increased by 7.3% and is now trading at $2.95. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) announced its quarterly earnings results on Monday, May, 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. The business had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.16 million. Perspective Therapeutics had a negative trailing twelve-month return on equity of 42.33% and a negative net margin of 17,982.69%. When did Perspective Therapeutics' stock split? Perspective Therapeutics shares reverse split on Monday, June 17th 2024.The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Perspective Therapeutics' major shareholders? Perspective Therapeutics' top institutional investors include Commodore Capital LP (5.56%), Avidity Partners Management LP (5.30%), Affinity Asset Advisors LLC (2.77%) and Spruce Street Capital LP (2.30%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann, Jonathan Robert Hunt, Johan M Spoor, Juan Graham, Heidi Henson and Robert F Williamson III. View institutional ownership trends. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/11/2026Today6/18/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 2 weeks, CATX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSEAMERICAN:CATX Previous SymbolNYSE:CATX CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees70Year FoundedN/APrice Target and Rating Average Price Target for Perspective Therapeutics$12.63 High Price Target$16.00 Low Price Target$8.00 Potential Upside/Downside+328.0%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$103.12 million Net Margins-17,982.69% Pretax Margin-18,194.18% Return on Equity-42.33% Return on Assets-35.05% Debt Debt-to-Equity RatioN/A Current Ratio8.75 Quick Ratio8.75 Sales & Book Value Annual Sales$880 thousand Price / Sales382.33 Cash FlowN/A Price / Cash FlowN/A Book Value$2.79 per share Price / Book1.06Miscellaneous Outstanding Shares114,050,000Free Float110,636,000Market Cap$336.45 million OptionableOptionable Beta1.71 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSEAMERICAN:CATX) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredDo NOT buy or sell SPCX before reading thisSpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much...Altimetry | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredHopeless About Retirement? Hopeless and Helpless Aren’t the Same ThingYour retirement date didn't move once - it moved slowly, then repeatedly, until the shift felt normal. That's ...Golden Portfolio | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredTrump’s New Dollar revealedThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...Porter & Company | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
